Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
about
Canadian clinical practice guidelines for acute and chronic rhinosinusitis.Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacyTigecycline: a review of a new glycylcycline antibioticCanadian guidelines for acute bacterial rhinosinusitis: clinical summary.Management of acute otitis media.Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmasIDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.Delafloxacin: design, development and potential place in therapyPotential role of tigecycline in the treatment of community-acquired bacterial pneumonia.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulationTigecycline: a new glycylcycline for treatment of serious infections.Tigecycline: a novel glycylcycline antibiotic.Antibiotic susceptibility of invasive Haemophilus influenzae strains in Canada.Role of gemifloxacin in community-acquired pneumonia.New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.Gemifloxacin: a new fluoroquinolone.High nasopharyngeal carriage of drug resistant Streptococcus pneumoniae and Haemophilus influenzae in North Indian schoolchildren.New treatment options for lower respiratory tract infections.In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agentsAntibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren.In vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents.Lignes directrices canadiennes sur la rhinosinusite bactérienne aiguë: Résumé clinique.Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolates.In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis.La prise en charge de l’otite moyenne aiguë.Guidelines for the Antibiotic Use in Adults with Acute Upper Respiratory Tract Infections.What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.
P2860
Q21245393-C987D67C-0834-4162-A56E-079027A17E8DQ26824268-4CF0170D-F0E1-46AD-9B7A-5347656A10EAQ28278979-430CC51B-2560-457D-915F-33CFDCF6FDC4Q30414121-6EDEAD98-4096-480F-B94F-1807CF5AE871Q34023743-E3C6CF72-2D2F-4F45-A213-D2DD3FF3EE12Q34230978-F6A5C4C6-7A36-460D-B082-80217CF405B5Q34262840-B8A265E8-4607-4715-B88B-D43EB0B69379Q34281970-7AB4E5E4-AF3E-4EF2-B4FF-F39136946C95Q34554381-3EBA1D21-4186-412D-AAE2-7BD52599C8F4Q35026616-E51FBC40-61B1-4EC0-976B-98CEB7D7B484Q35637071-27F9896F-9442-4BDE-9FE8-2FF8F7A19CF4Q35644095-6E0D94E2-716C-4071-B70E-533D9D4756F8Q36218312-26CBABD4-1C56-4B28-AB41-CBAE1FFEBA46Q36379330-146E9879-7088-4CAB-9804-6B412575EABDQ36538660-DC5BA121-95CF-463D-8CCD-289304F65D0AQ37228717-A004C28F-8A7F-4029-9DF8-0C6E3B7AE04EQ37274639-4BCD64F0-0FF6-4F46-8E91-4B11B3425B99Q37489476-8EA86C18-561B-42DA-8DED-C296EF9876B5Q37867123-799372FC-5891-4AC6-87A7-D89BF1541B5BQ39708722-3D8579FB-38EE-4BAF-81BB-44275382D639Q40111519-1CF9E78D-36F2-406A-B9A0-386FF53F2424Q41194442-F8B9CB48-A6C8-4A76-A890-A770E9656491Q41715331-125E5E8B-27B2-48A5-B056-10B40C512250Q43010590-C0C42025-F933-4299-B0AF-66DB4BD343B9Q44216703-D84B7426-189E-4768-B2F5-C21928941ECDQ46055056-7579ECD0-3528-479F-90A8-835BFA3652FDQ46226517-066228F1-6834-47A6-9124-4186DEF05F1FQ46404215-06345BA8-6C38-4066-B159-1578040A5895Q46663195-AD5F9BAD-390E-4DDF-927E-560B99E92008Q47131898-043FC748-5C63-44DC-B2C8-CE1675A121A9Q47665624-F801EDF1-AB69-42A6-9303-85C750F207D0Q47736241-BF092B91-E8D2-4DAE-B3A6-C7D6D4C9654B
P2860
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antimicrobial resistance in Ha ...... eptibility Study, 1997 to 2002
@ast
Antimicrobial resistance in Ha ...... eptibility Study, 1997 to 2002
@en
type
label
Antimicrobial resistance in Ha ...... eptibility Study, 1997 to 2002
@ast
Antimicrobial resistance in Ha ...... eptibility Study, 1997 to 2002
@en
prefLabel
Antimicrobial resistance in Ha ...... eptibility Study, 1997 to 2002
@ast
Antimicrobial resistance in Ha ...... eptibility Study, 1997 to 2002
@en
P2093
P2860
P1476
Antimicrobial resistance in Ha ...... eptibility Study, 1997 to 2002
@en
P2093
CROSS Study Group
Daryl J Hoban
Kimberly A Nichol
Lorraine Palatnick
P2860
P304
P356
10.1128/AAC.47.6.1875-1881.2003
P407
P577
2003-06-01T00:00:00Z